Table 3.
Summary of clinical studies involving the use of isolated hADSCs on arm disorders for the last 10 years.
| Target Disorder | No. of Patients Treated (Age: Mean ± SD) |
ADSC Type | ADSC Delivery |
Study Outcome |
Year | Ref. No. | |
|---|---|---|---|---|---|---|---|
| 1 | Lateral epicondylosis |
12 (51.85 ± 13.86) | Allogeneic | Intratendinous injection with fibrin glue | Safe and improved elbow pain (VAS 1), performance (MEPI 2), and structural defects | 2015 | [141] |
| 2 | chronic lateral elbow tendinopathy |
18 (46.5 ± NA 3) | Autologous, derived from periumbilical zone | Percutaneous injection to the affected elbow | Significantly improved mean VAS scores for maximum pain score, QuickDASH 4-Compulsory score, QuickDASH-Sport score | 2021 | [142] |
| 3 | Rotator cuff tears | 72 (59.05 ± 3.60) | Autologous, derived from buttocks | ADSC loaded in fibrin glue was injected | Although ADSC significantly improved structural outcomes in terms of the retear rate, there were no clinical differences compared to the control group | 2017 | [143] |
| 4 | Rotator cuff tears | 11 (64.60 ± 9.60) | Autologous, derived from either the periumbilical abdominal area, bilateral flanks, or medial thigh fat | Intra-articular injection | Significantly higher mean ASES 5 total scores without adverse events | 2020 | [144] |
| 5 | Anterior cruciate ligament reconstruction | 20 (24.70 ± 4.70) | Autologous, derived from abdominal or inner thigh fat | Intra-articular injection, applied to BTB 6 autograft | Although ADSC significantly improved knee function and healing/maturation of the graft, it was not significantly different compared to the control group | 2019 | [145] |
1 Visual analog scale (VAS); 2 Mayo clinic performance index (MEPI); 3 not available; 4 mean quick disabilities of the arm, shoulder, and hand; 5 American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES); 6 bone-patellar tendon-bone (BTB).